Evidence map›Paper›PMID 39566985›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Quantifying the Reversibility of Clofazimine-induced Pigmentation in a Patient with Mycobacterium abscessus Pulmonary Disease.

Masashi Ito, Fumiya Watanabe, Koji Furuuchi, Keiji Fujiwara, Tatsuya Kodama, Takashi Ohe, Yoshiaki Tanaka, Takashi Yoshiyama, Ken Ohta, Kozo Morimoto

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masashi ItoRespiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
Fumiya WatanabeDepartment of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University, Japan.
Koji FuruuchiRespiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
Keiji FujiwaraRespiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
Tatsuya KodamaRespiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
Takashi OheRespiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
Yoshiaki TanakaRespiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
Takashi YoshiyamaRespiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
Ken OhtaRespiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.
Kozo MorimotoRespiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 45-year-old woman with Mycobacterium abscessus pulmonary disease was treated with multidrug therapy, including clofazimine, at Fukujuji Hospital. Six months after clofazimine initiation, the treatment was discontinued at the patient's request due to hyperpigmentation. Pigmentation is a critical side effect of clofazimine. We quantified clofazimine-induced pigmentation on her face using NeoVoirI

Indexed as

ClofazimineHyperpigmentationLung DiseasesMycobacterium abscessusMycobacterium Infections, NontuberculousFemaleHumansMiddle AgedClofazimineclofazimineMycobacterium abscessusMycobacterium avium complexnontuberculous mycobacteriapigmentation

Identifiers

PMID39566985
PMCPMC12241785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.